Retatrutide is often nicknamed “GLP-3” online, but its actual description is a triple hormone receptor agonist. The three targets are GIP, GLP-1 and glucagon receptors. It is not a newly numbered GLP hormone, and “triple” does not mean three separate peptides mixed into one pen. Lilly's explanation identifies the molecule and its targets.
One molecule, three receptor targets
A receptor agonist activates a receptor. The name describes where a molecule can act; it does not count the number of ingredients on a product label.
| Term | What it describes |
|---|---|
| GLP-1 receptor | One of retatrutide's three receptor targets |
| GIP receptor | A second target, also relevant to tirzepatide |
| Glucagon receptor | The additional target in retatrutide's triple-agonist description |
| Peptide blend | A formulation listing two or more separate ingredients |
That distinction also explains why a blend and a multi-receptor agonist are not two names for the same type of product.
Why the nickname can confuse a product search
Someone searching “GLP-3 pen” may mean retatrutide, a supposed next generation of weight-loss medicine or simply a product marketed with that phrase. Those searches do not guarantee that every result contains the same ingredient.
Use the full compound name when checking a listing and its documents. “Retatrutide,” “triple agonist” and a specific total-content amount together provide more information than a nickname alone. A marketing label should not replace the ingredient identity.
How it differs from tirzepatide
Tirzepatide has GIP and GLP-1 receptor activity. Retatrutide adds glucagon-receptor activity to its target profile. The original tirzepatide development report describes the dual-agonist molecule.
Counting targets does not, by itself, predict a person's response or establish which treatment is appropriate. The receptor description explains the biological design. Clinical studies assess outcomes in particular populations using particular preparations.
The same logic applies to a two-ingredient catalog blend. Two ingredients are not automatically two complementary clinical effects, and three receptor targets are not three times the benefit.
What to check on a SimplePeptide listing
The Retatrutide page identifies a 32 mg pen. The Tirzepatide page offers 30 mg and 60 mg formats. These numbers describe total labelled contents, not a conversion between the two molecules.
If a seller uses “GLP-3,” ask for the exact ingredient name and applicable documentation. That resolves the naming question more effectively than comparing slogans. Retatrutide remains investigational; a familiar nickname does not change its status or establish that a retail product matches the clinical-trial preparation.
Sources are linked beside the statements they support. Product prices and specifications were checked on 16 October 2026; confirm current details on the product page.